Literature DB >> 11490155

IgG-mediated histamine release from canine mastocytoma-derived cells.

T Takahashi1, S Kitani, M Nagase, M Mochizuki, R Nishimura, Y Morita, N Sasaki.   

Abstract

BACKGROUND: Recent data suggest that normal tissue mast cells can express functional receptors for IgG under certain conditions. However, little is known about IgG receptor expression and functional consequences in mast cell neoplasms.
METHODS: In this study, neoplastic mast cells were obtained from a dog with cutaneous mastocytoma (CM-MC) and from a dog with visceral mastocytoma (VI-MC). Both cell populations were characterized morphologically and functionally.
RESULTS: Most cells proliferated constantly in suspension without particular supplements. Doubling times of CM-MC and VI-MC were 52.2 and 27.5 h, respectively. Both cell types were sensitive to formalin fixation, did not contain heparin and were tryptase and chymase positive. Electron microscopy showed fine granules with electron-dense content in both cell populations. The total histamine content of CM-MC and VI-MC was 0.25 and 0.10 pg/cell, respectively. Calcium ionophore A23187 and substance P induced dose-dependent histamine release, whereas compound 48/80 had no effect. Most significantly, both cell types, when sensitized with monomeric dog IgG, released histamine upon stimulation by anti-dog IgG.
CONCLUSIONS: Dog mastocytoma-derived cells may be useful to study the regulation of neoplastic mast cell growth and differentiation, as well as IgG receptor-mediated activation in neoplastic mast cells. Further research is required to clarify the pathophysiological significance of constitutive expression of IgG receptors in neoplastic (canine) mast cells. Copyright 2001 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11490155     DOI: 10.1159/000053820

Source DB:  PubMed          Journal:  Int Arch Allergy Immunol        ISSN: 1018-2438            Impact factor:   2.749


  6 in total

1.  Generation and characterization of novel canine malignant mast cell line CL1.

Authors:  Tzu-Yin Lin; Rachael Thomas; Pei-Chien Tsai; Matthew Breen; Cheryl A London
Journal:  Vet Immunol Immunopathol       Date:  2008-10-11       Impact factor: 2.046

2.  The radiosensitizing effect of the aurora kinase inhibitors, ENMD-2076, on canine mast cell tumours in vitro.

Authors:  K Shiomitsu; E Sajo; C Rubin; I Sehgal
Journal:  Vet Comp Oncol       Date:  2013-06-13       Impact factor: 2.613

3.  Presence and primary sequence of a high-affinity IgG receptor on canine mastocytoma (CM-MC) cells.

Authors:  Ryosuke Nakamura; Yoshitaka Sato; Kayoko Takagi; Nobuo Sasaki; Jun-ichi Sawada; Seiichi Kitani; Reiko Teshima
Journal:  Immunogenetics       Date:  2003-06-17       Impact factor: 2.846

4.  Oncolytic reovirus in canine mast cell tumor.

Authors:  Chung Chew Hwang; Saori Umeki; Masahito Kubo; Toshiharu Hayashi; Hiroshi Shimoda; Masami Mochizuki; Ken Maeda; Kenji Baba; Hiroko Hiraoka; Matt Coffey; Masaru Okuda; Takuya Mizuno
Journal:  PLoS One       Date:  2013-09-20       Impact factor: 3.240

5.  Intercellular interactions between mast cells and stromal fibroblasts obtained from canine cutaneous mast cell tumours.

Authors:  Lidia H Pulz; Yonara G Cordeiro; Greice C Huete; Karine G Cadrobbi; Arina L Rochetti; Pedro L P Xavier; Adriana Tomoko Nishiya; Silvio Henrique de Freitas; Heidge Fukumasu; Ricardo F Strefezzi
Journal:  Sci Rep       Date:  2021-12-13       Impact factor: 4.379

6.  Expression of PD-L1 on canine tumor cells and enhancement of IFN-γ production from tumor-infiltrating cells by PD-L1 blockade.

Authors:  Naoya Maekawa; Satoru Konnai; Ryoyo Ikebuchi; Tomohiro Okagawa; Mami Adachi; Satoshi Takagi; Yumiko Kagawa; Chie Nakajima; Yasuhiko Suzuki; Shiro Murata; Kazuhiko Ohashi
Journal:  PLoS One       Date:  2014-06-10       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.